Helena Dahlbäck

Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants

Aim Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption,...